Key result
Activating somatic mutations of the beta-catenin gene were identified in 27% of benign and 31% of malignant adrenocortical tumors, representing a frequent genetic defect.
Population
39 adrenocortical tumors and adrenocortical cancer H295R cell line
Design
Other
Authors
Loading...
May warrant Wnt/beta-catenin inhibitor trials in adrenocortical tumors; leaves open clinical adoption pending prospective validation.
Observational (n=39)
Activating mutations of the Wnt/beta-catenin signaling pathway are frequent in both benign and malignant adrenocortical tumors, suggesting a potential therapeutic target.
Tissier et al. (2005) conducted an observational in Adrenocortical tumors (n=39). Beta-catenin mutations was evaluated on Prevalence of beta-catenin mutations and abnormal accumulation. Activating somatic mutations of the beta-catenin gene were identified in 27% of benign and 31% of malignant adrenocortical tumors, representing a frequent genetic defect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: